

# Danieli Castro O Andrade

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2577146/publications.pdf>

Version: 2024-02-01

60  
papers

1,595  
citations

393982

19  
h-index

329751

37  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1729  
citing authors

#	ARTICLE	IF	CITATIONS
1	14th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Autoimmunity Reviews</i> , 2014, 13, 685-696.	2.5	290
2	Brief Report: Induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. <i>Arthritis and Rheumatism</i> , 2012, 64, 2719-2723.	6.7	176
3	Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 740-746.	0.5	89
4	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	0.8	80
5	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 464-468.	1.6	79
6	Interferon $\alpha$ and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia. <i>Arthritis and Rheumatology</i> , 2015, 67, 977-987.	2.9	64
7	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1490-1501.	1.5	60
8	Neurologic manifestations of antiphospholipid syndrome. <i>Lupus</i> , 2018, 27, 1404-1414.	0.8	49
9	Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB/c mice: a promising model for studying human disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 2764-2773.		45
10	Extra-criteria manifestations of antiphospholipid syndrome: Risk assessment and management. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 117-120.	1.6	42
11	Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2022, 74, 324-335.	1.5	39
12	Emerging Therapies in Antiphospholipid Syndrome. <i>Current Rheumatology Reports</i> , 2016, 18, 22.	2.1	37
13	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019, 71, 134-141.	1.5	37
14	Enhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. <i>Autoimmunity Reviews</i> , 2019, 18, 393-398.	2.5	30
15	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1036-1043.	0.5	30
16	Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2019, 126, 656-661.	1.1	29
17	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020, 29, 1353-1363.	0.8	28
18	Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2022, 74, 562-571.	1.5	25

#	ARTICLE	IF	CITATIONS
19	Update on antiphospholipid antibody syndrome. Revista Da Associação Médica Brasileira, 2017, 63, 994-999.	0.3	22
20	High frequency of osteoporosis and fractures in women with dermatomyositis/polymyositis. Rheumatology International, 2012, 32, 1549-1553.	1.5	21
21	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). Lupus, 2021, 30, 2276-2285.	0.8	21
22	Primary antiphospholipid syndrome: absence of premature atherosclerosis in patients without traditional coronary artery disease risk factors. Lupus, 2016, 25, 472-478.	0.8	19
23	A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution. Rheumatology, 2020, 59, 2412-2418.	0.9	19
24	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. Journal of Rheumatology, 2021, 48, 541-547.	1.0	19
25	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
26	Difficult Clinical Situations in the Antiphospholipid Syndrome. Current Rheumatology Reports, 2015, 17, 29.	2.1	18
27	Omega-3 Fatty Acid Supplementation Improves Endothelial Function in Primary Antiphospholipid Syndrome: A Small-Scale Randomized Double-Blind Placebo-Controlled Trial. Frontiers in Immunology, 2018, 9, 336.	2.2	14
28	The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Thrombosis Research, 2019, 175, 32-36.	0.8	13
29	Global antiphospholipid syndrome score and anti-β <sub>2</sub> -glycoprotein I domain I for thrombotic risk stratification in antiphospholipid syndrome: A four-year prospective study. Lupus, 2020, 29, 676-685.	0.8	13
30	Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome. Lupus, 2022, 31, 974-984.	0.8	13
31	AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 5-Year Update. Current Rheumatology Reports, 2016, 18, 64.	2.1	12
32	Systemic sclerosis induced by the use of cocaine: is there an association?. Rheumatology International, 2019, 39, 387-393.	1.5	12
33	Pregnancy outcomes in mixed connective tissue disease: a multicentre study. Rheumatology, 2019, 58, 2000-2008.	0.9	10
34	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. Journal of Thrombosis and Haemostasis, 2019, 17, 2069-2080.	1.9	9
35	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. Current Rheumatology Reports, 2021, 23, 45.	2.1	9
36	Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (â€ Registryâ€™). Lupus Science and Medicine, 2022, 9, e000633.	1.1	9

#	ARTICLE	IF	CITATIONS
37	Quantifying subclinical central nervous lesions in primary antiphospholipid syndrome: The role of magnetization transfer imaging. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 483-488.	1.9	8
38	Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. <i>Arthritis Care and Research</i> , 2021, 73, 1804-1808.	1.5	7
39	Cognitive dysfunction and serum levels of brain-derived neurotrophic factor (BDNF) in primary anti-phospholipid syndrome (PAPS). <i>Rheumatology</i> , 2021, 60, 179-187.	0.9	6
40	Identification of Autoimmunity to Peptides of Collagen V $\pm$ 1 Chain as Newly Biomarkers of Early Stage of Systemic Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 604602.	2.2	6
41	Benefits of Home-Based Exercise Training Following Critical SARS-CoV-2 Infection: A Case Report. <i>Frontiers in Sports and Active Living</i> , 2021, 3, 791703.	0.9	6
42	ABO blood group in primary antiphospholipid syndrome: influence in the site of thrombosis?. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 374-378.	1.0	5
43	Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?. <i>Lupus</i> , 2021, 30, 1732-1738.	0.8	5
44	Immunogenicity and safety of primary fractional-dose yellow fever vaccine in autoimmune rheumatic diseases. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010002.	1.3	5
45	Managing Antiphospholipid Syndrome in Children and Adolescents: Current and Future Prospects. <i>Paediatric Drugs</i> , 2022, 24, 13-27.	1.3	5
46	Anti-collagen type v: a marker of early systemic sclerosis?. <i>Advances in Rheumatology</i> , 2019, 59, 19.	0.8	4
47	Diagnosis and Management of Gastric Antral Vascular Ectasia. <i>Journal of Clinical Rheumatology</i> , 2020, 26, 79-81.	0.5	4
48	Antiphospholipid Syndrome Committee of the Brazilian Society of Rheumatology position statement on the use of direct oral anticoagulants (DOACs) in antiphospholipid syndrome (APS). <i>Advances in Rheumatology</i> , 2020, 60, 29.	0.8	4
49	Treatment of Non-criteria Manifestations in Antiphospholipid Syndrome. , 2017, , 247-266.		4
50	Non-criteria Antiphospholipid Antibodies: a narrative review. <i>Revista Da Associação Médica Brasileira</i> , 2020, 66, 1595-1601.	0.3	4
51	CoaguChek® XS versus standard laboratory prothrombin time for anticoagulant monitoring in patients with antiphospholipid syndrome. <i>Lupus</i> , 2022, 31, 565-574.	0.8	3
52	Clinical and laboratory profile of juvenile-onset systemic sclerosis in a Brazilian cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 43-48.	1.0	2
53	Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients. <i>Journal of Applied Physiology</i> , 2022, 132, 682-688.	1.2	2
54	Eosinophilic fasciitis during pregnancy: case report and review of literature. <i>Rheumatology International</i> , 2018, 38, 525-529.	1.5	1

#	ARTICLE	IF	CITATIONS
55	Anorectal diseases in patients with Antiphospholipid syndrome: a cross-sectional study. <i>Advances in Rheumatology</i> , 2020, 60, 51.	0.8	1
56	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION). , 2017, , 267-276.		1
57	William Habib Chahade 5th October 1941â€“4th January 2017. <i>Lupus</i> , 2017, 26, 671-671.	0.8	0
58	Budd-Chiari syndrome, large regenerative nodules and hepatocellular carcinoma in antiphospholipid syndrome associated with juvenile systemic lupus erythematosus. <i>Modern Rheumatology Case Reports</i> , 2018, 2, 20-24.	0.3	0
59	Distinct features of youth-onset primary antiphospholipid syndrome. <i>Lupus</i> , 2021, 30, 1888-1895.	0.8	0
60	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021, 61, 64.	0.8	0